← Back to Search

Other

BMS-986196 and Loestrin for Healthy Female Volunteers

Phase 1

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at day 1 and day 20

Awards & highlights

Study Summary

This trial looks at how BMS-986196 affects birth control when taken together.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at day 1 and day 20

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at day 1 and day 20

This trial's timeline: 3 weeks for screening, Varies for treatment, and at day 1 and day 20 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC [INF])

Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])

Maximum observed plasma concentration (Cmax)

Secondary outcome measures

Apparent total body clearance (CLT/F)

Number of participants with Adverse Events (AEs)

Number of participants with Serious AEs (SAEs)

+7 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: BMS-986196 and LoestrinExperimental Treatment2 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BMS-986196

2021

Completed Phase 1

~140

Loestrin

2022

Completed Phase 1

~140

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor

2,642 Previous Clinical Trials

4,130,109 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical trial offer enrollment to individuals aged sixty and above?

"Potential participants for this trial must be above the age of consent and younger than 45 years old."

Answered by AI

Is it possible to become a participant in this clinical trial?

"To qualify for enrollment in this research study, applicants must be female and between 18 to 45 years of age. 15 individuals will ultimately join the trial."

Answered by AI

Is this study still taking on participants?

"Affirmative. Clinicaltrials.gov states that this ongoing research is currently recruiting, commencing on June 6th 2023 and having its information updated as recently as July 24th 2023. The trial seeks to include 15 participants from 1 site of enrollment."

Answered by AI

How hazardous are BMS-986196 and Loestrin when ingested?

"BMS-986196 and Loestrin both receive a safety score of 1 due to the limited evidence available in Phase 1 trials. These drugs have not been thoroughly tested for efficacy or safety yet."

Answered by AI

What is the total enrollment number for this research endeavor?

"Affirmative, the information on clinicaltrials.gov confirms that this experiment is actively seeking to enrol volunteers; it was first posted on June 6th 2023 and last updated July 24th 2023. Currently, 15 participants are needed from 1 trial site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants

2023. "A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05891262.